SBIR/STTR Research Award

Biomarker Matrix for Genotoxicity Mode of Action

Award identifier ccc30ebe6c43c602973021240139cc6865d2d6bbc4c61695eba2b8af0685e5a6Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$976,469

Program and phase

SBIR · Phase II

Award year

2015

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
Litron Laboratories Ltd
Proposal award date
2015-02-01
Contract end date
2017-01-31
UEI
LJH7LE9AUHL5
Solicitation number
PA13-234
Topic code
NIEHS

Research abstract

DESCRIPTION provided by applicant It is well recognized that current batteries of genetic toxicology assays exhibit relatively high sensitivity meaning they effectively identify genotoxic carcinogens However a critical deficiency with current approaches exists namely the specificity of the in vitro mammalian cell genotoxicity tests is low as they yield a high incidenc of positive results that do not have in vivo relevance so called andquot misleadingandquot or andquot irrelevantandquot positives This high incidence of irrelevant in vitro positive results leads to extensive and costy additional testing often with whole animal models or else abandonment of potentially valuable products We will address this major problem with current in vitro mammalian cell genetic toxicity assays by developing commercial kits that enable an automated testing strategy that exhibits both high sensitivity and specificity This system will categorize positive results according to the predominant mode of genotoxic activity and importantly will reliably identify irrelevant mode s of action that are likely to be nonoperational in vivo A secondary objective of the proposed work is the development of methods for characterizing clastogens That is we will develop tools that elucidate whether clastogenic activity is the result of DNA reactivity or whether it is mediated by an indirect mechanism PUBLIC HEALTH RELEVANCE Sub lethal DNA damage that cannot be faithfully repaired results in gene mutation and or chromosomal aberrations and these effects are known to contribute to carcinogenesis There is also emerging evidence that DNA damage contributes to germline genetic disorders and other disease sequelae for instance atherosclerosis Thus there is an important need for sensitive and specific assays to evaluate chemicals for genotoxic potential Furthermore in cases when genotoxic potential has been determined more efficient means of elucidating genotoxic mode of action would be useful for understanding human health risks

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

42 SBIR/STTR records share this UEI (1985–2025). Reported award amounts total $18,400,554. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Health and Human Services, National Science Foundation

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.